The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker
Oral Diseases · 2025
DOI: 10.1111/odi.15396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Sibel Elif Gultekin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, Faculty of Dentistry, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Ameloblastoma, Biomarkers, Tumor, Vimentin, Jaw Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marga and Walter Boll Stiftung, Kerpen, Germany, The Scientific and Technological Research Council of Turkey (TUBITAK) - Deutscher Akademischer Austauschdienst (DAAD) - Bilateral Cooperation Funding Program.…, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
Introduction
Ameloblastoma (ABL), a common odontogenic tumor in the maxillofacial region, presents primarily as unicystic (U‐ABL) and conventional (C‐ABL) variants. Despite shared epithelial features, their distinct biological behaviors may stem from interactions between connective tissue and epithelial cells. Vimentin 3 (VIM3), a truncated variant of Vimentin‐Full Length (VIMFL), exhibits unique biological properties. This study is the first to investigate VIM3 expression in ABLs.
Methods
Formalin‐fixed paraffin‐embedded (FFPE) samples of C‐ABL ( n = 30), U‐ABL ( n = 30), and dental follicles (DF, n = 30) were analyzed. Immunohistochemical evaluation of VIM3, VIMFL, WNT5a, and MTCO1 was performed, alongside qRT‐PCR for VIM3, VIMFL, WNT5a, ROR2, and miR‐498.
Results
VIM3 expression was significantly higher in C‐ABL ( p < 0.0001) compared to U‐ABL and DFs. VIMFL was absent in the epithelial components of all cases. C‐ABL showed significantly higher WNT5a ( p < 0.0001) and MTCO1 ( p = 0.0327) expression. qRT‐PCR revealed significant differences in VIM3 and miR‐498 levels between U‐ABL and DFs ( p < 0.0001). No significant differences were found for WNT5a, VIMFL, or ROR2 ( p > 0.05).
Conclusion
This study identifies VIM3 expression in ABLs, distinct from VIMFL, suggesting its potential as a biomarker. Additionally, mitochondrial dysfunction may play a role in ABL tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathology, Faculty of Dentistry, Gazi University, Ankara, Turkey.
- Clinic and Polyclinic for Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
ORCID-Profile: Sibel Elif Gultekin, Melanie von Brandenstein, Emre Baris, Ipek Atak Secen, Leyla Arslan Bozdag, Heike Goebel
Förderung
- Marga and Walter Boll Stiftung, Kerpen, Germany
- The Scientific and Technological Research Council of Turkey (TUBITAK) - Deutscher Akademischer Austauschdienst (DAAD) - Bilateral Cooperation Funding Program.…
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Gultekin, S. E., von Brandenstein, M., Baris, E., Atak Secen, I., Arslan Bozdag, L., & Goebel, H. (2025). The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker. Oral Diseases. https://doi.org/10.1111/odi.15396
Vancouver
Gultekin SE, von Brandenstein M, Baris E, Atak Secen I, Arslan Bozdag L, Goebel H. The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker. Oral Diseases. 2025. doi:10.1111/odi.15396
BibTeX
@article{Gultekin2025,
author = {Gultekin, Sibel Elif and von Brandenstein, Melanie and Baris, Emre and Atak Secen, Ipek and Arslan Bozdag, Leyla and Goebel, Heike},
title = {The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15396}
}
EUVIMED